Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Completes $750 Million Secondary Offering

publication date: Jan 19, 2018

BeiGene, a Beijing innovative cancer biotech, raised a spectacular $750 million in a secondary offering of its shares. The price of the shares ended the session 13% higher after the funding was announced, closing the day at $115.56. BeiGene now has a market capitalization of $4.8 billion -- before the new shares are issued. In 2016, BeiGene staged a $158 million IPO on the Nasdaq exchange, pricing at $24 per share. To date, the company has raised almost $1 billion, including the IPO, a $200 million secondary offering, and Celgene's $236 million payment plus $150 investment in BeiGene shares for ex-China rights to BeiGene's PD-1 candidate. More details....

Stock Symbols: (NSDQ: BGNE) (NSDQ: CELG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.